Related Experiment Videos
Pathological changes in prostate lesions after androgen manipulation
1Institute of Pathological Anatomy and Histopathology, University of Ancona, Ospedale Regionale, Torrette, Italy. r.montironi@popcsi.unian.it
Abstract:
The number of newly diagnosed cases of prostate cancer has doubled in the past four years because of the aging of the population coupled with growing awareness of the importance of early detection. The issues of clinical understaging and resection limit positivity have led to the development of novel management practices, including neoadjuvant hormonal treatment, which aims to downstage the primary tumour and decrease the positive margin rate before definitive localised treatment (radical prostatectomy or definitive radiation treatment (neoadjuvant)). There is conflicting evidence regarding pathological downstaging, with some studies suggesting benefit and others no benefit of androgen manipulation before radical prostatectomy. The problem might be related to incomplete sampling of the prostates and difficulties associated with the pathological interpretation of morphological changes. The least controversial aspect of neoadjuvant treatment is its impact on surgical margins. Most series have shown that neoadjuvant treatment in clinical T2 tumours is associated with a 20-25% decrease in positive margins in radical prostatectomy specimens. In patients with clinical T3 tumours, the effects of neoadjuvant treatment on positive margins are less clear. Even if some early significant advantages can be observed following hormonal treatment this may not alter the metastatic spread and overall survival rate. Only long term follow up studies evaluating biological and clinical failures, time to progression, and survival will allow definitive conclusions from this approach.
Insights
Neoadjuvant hormonal treatment may reduce positive surgical margins in prostate cancer patients, particularly those with clinical T2 tumors. However, its impact on downstaging and long-term survival remains uncertain, requiring further investigation.
Area of Science:
- Oncology
- Urology
Background:
- Prostate cancer diagnoses are increasing due to an aging population and improved early detection awareness.
- Clinical understaging and positive resection margins necessitate advanced management strategies.
- Neoadjuvant hormonal treatment is explored to reduce tumor size and positive margins before definitive treatment.
Purpose of the Study:
- To evaluate the effectiveness of neoadjuvant hormonal treatment in prostate cancer management.
- To assess the impact of neoadjuvant hormonal therapy on pathological downstaging and surgical margin positivity.
- To review the existing evidence on androgen manipulation prior to radical prostatectomy.
Main Methods:
- Review of existing studies on neoadjuvant hormonal treatment for prostate cancer.
- Analysis of pathological data regarding tumor downstaging and margin status.
- Comparison of outcomes in clinical T2 and T3 tumors receiving neoadjuvant therapy.
Main Results:
- Neoadjuvant treatment is associated with a 20-25% decrease in positive margins for clinical T2 tumors undergoing radical prostatectomy.
- Evidence regarding pathological downstaging is conflicting, with some studies showing benefit and others none.
- The effect of neoadjuvant treatment on positive margins in clinical T3 tumors is less clear.
Conclusions:
- Neoadjuvant hormonal treatment shows a consistent benefit in reducing positive surgical margins for localized prostate cancer (T2).
- The impact on pathological downstaging and long-term outcomes like survival requires further long-term follow-up studies.
- More research is needed to definitively establish the role of neoadjuvant hormonal therapy in altering metastatic spread and overall survival.